Literature DB >> 30700544

Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.

Chrysovalantis Voutouri1, Nathaniel D Kirkpatrick2, Euiheon Chung2, Fotios Mpekris1, James W Baish3, Lance L Munn2, Dai Fukumura2, Triantafyllos Stylianopoulos4, Rakesh K Jain5.   

Abstract

Cooption of the host vasculature is a strategy that some cancers use to sustain tumor progression without-or before-angiogenesis or in response to antiangiogenic therapy. Facilitated by certain growth factors, cooption can mediate tumor infiltration and confer resistance to antiangiogenic drugs. Unfortunately, this mode of tumor progression is difficult to target because the underlying mechanisms are not fully understood. Here, we analyzed the dynamics of vessel cooption during tumor progression and in response to antiangiogenic treatment in gliomas and brain metastases. We followed tumor evolution during escape from antiangiogenic treatment as cancer cells coopted, and apparently mechanically compressed, host vessels. To gain deeper understanding, we developed a mathematical model, which incorporated compression of coopted vessels, resulting in hypoxia and formation of new vessels by angiogenesis. Even if antiangiogenic therapy can block such secondary angiogenesis, the tumor can sustain itself by coopting existing vessels. Hence, tumor progression can only be stopped by combination therapies that judiciously block both angiogenesis and cooption. Furthermore, the model suggests that sequential blockade is likely to be more beneficial than simultaneous blockade.

Entities:  

Keywords:  Ang2; VEGF; antiangiogenic treatment; glioblastoma; hypoxia

Mesh:

Substances:

Year:  2019        PMID: 30700544      PMCID: PMC6377457          DOI: 10.1073/pnas.1818322116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

Review 1.  Vascular-specific growth factors and blood vessel formation.

Authors:  G D Yancopoulos; S Davis; N W Gale; J S Rudge; S J Wiegand; J Holash
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

2.  Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.

Authors:  S A Rempel; S Dudas; S Ge; J A Gutiérrez
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

Review 3.  Mathematical modelling of angiogenesis.

Authors:  M A Chaplain
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

Authors:  P Kunkel; U Ulbricht; P Bohlen; M A Brockmann; R Fillbrandt; D Stavrou; M Westphal; K Lamszus
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

Review 5.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

6.  Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.

Authors:  G Griffon-Etienne; Y Boucher; C Brekken; H D Suit; R K Jain
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

7.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.

Authors:  J L Rubenstein; J Kim; T Ozawa; M Zhang; M Westphal; D F Deen; M A Shuman
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

8.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

Authors:  J Holash; P C Maisonpierre; D Compton; P Boland; C R Alexander; D Zagzag; G D Yancopoulos; S J Wiegand
Journal:  Science       Date:  1999-06-18       Impact factor: 47.728

9.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo.

Authors:  Ivan B Lobov; Peter C Brooks; Richard A Lang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

10.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

Authors:  Eugene S Kim; Anna Serur; Jianzhong Huang; Christina A Manley; Kimberly W McCrudden; Jason S Frischer; Samuel Z Soffer; Laurence Ring; Tamara New; Stephanie Zabski; John S Rudge; Jocelyn Holash; George D Yancopoulos; Jessica J Kandel; Darrell J Yamashiro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

View more
  28 in total

1.  MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage.

Authors:  Sophia F Magkouta; Apostolos G Pappas; Photene C Vaitsi; Panagiotis C Agioutantis; Ioannis S Pateras; Charalampos A Moschos; Marianthi P Iliopoulou; Chrysavgi N Kosti; Heleni V Loutrari; Vassilis G Gorgoulis; Ioannis T Kalomenidis
Journal:  JCI Insight       Date:  2020-06-18

Review 2.  Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway?

Authors:  Gabriele Grasmann; Elisabeth Smolle; Horst Olschewski; Katharina Leithner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 3.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

Review 4.  The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.

Authors:  Ying Shao; Bingjian Lu
Journal:  Cancer Metastasis Rev       Date:  2021-10-18       Impact factor: 9.264

Review 5.  An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment.

Authors:  Majid Sharifi; William C Cho; Asal Ansariesfahani; Rahil Tarharoudi; Hedyeh Malekisarvar; Soyar Sari; Samir Haj Bloukh; Zehra Edis; Mohamadreza Amin; Jason P Gleghorn; Timo L M Ten Hagen; Mojtaba Falahati
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

6.  Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?

Authors:  John D Martin; Dan G Duda; Rakesh K Jain
Journal:  Circ Res       Date:  2020-08-27       Impact factor: 17.367

Review 7.  Models and molecular mechanisms of blood vessel co-option by cancer cells.

Authors:  Yu Zhang; Sarah Wang; Andrew C Dudley
Journal:  Angiogenesis       Date:  2019-10-18       Impact factor: 9.596

Review 8.  Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier.

Authors:  Barrett D Allen; Charles L Limoli
Journal:  Free Radic Biol Med       Date:  2021-12-04       Impact factor: 7.376

Review 9.  Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment.

Authors:  Belén Delgado-Martín; Miguel Ángel Medina
Journal:  Adv Sci (Weinh)       Date:  2020-03-12       Impact factor: 16.806

Review 10.  Management of brain metastases according to molecular subtypes.

Authors:  Riccardo Soffietti; Manmeet Ahluwalia; Nancy Lin; Roberta Rudà
Journal:  Nat Rev Neurol       Date:  2020-09-01       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.